QDEL

AI Memo

QuidelOrtho

As of 2026-09-15/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-15 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

Third-quarter execution checkpoint • 2026-11-05

Base target: $13 / p=50% prob

Biggest risk

The apparent Q2 beat was overshadowed by a substantial guidance reset: the revenue midpoint fell from $2.725 billion to $2.56 billion, adjusted EBITDA midpoint from $622.5 million to $550 million, adjusted EPS midpoint from $1.90 to $0.775, and free-cash-flow guidance was withdrawn. China, respiratory demand, working capital, and leverage remain material uncertainties [#SEC-8K-2026-08-06].

Invalidation

Break below $8 or thesis failure.

What would change my mind?

Q2 revenue and adjusted EPS exceeded the stored third-party estimates, while ex-China revenue grew 6%, Point of Care grew 16%, and adjusted EBITDA margin improved to 20.5%. Stabilization in China or respiratory demand, combined with cost execution, could produce meaningful upside from the depressed share price [#SEC-8K-2026-08-06].

Research note

Recommendation

—

Confidence

medium

As of

2026-09-15

Base target

$13

p=50%

Bull target

$16

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

China, respiratory, and cash-flow pressure
Cash conversion and balance-sheet repair
Q2 revenue and adjusted EPS exceeded the stored third-party estimates, while ex-China revenue grew 6%, Point of Care grew 16%, and adjusted EBITDA margin improved to 20.5%.

BearKey bullets

A weaker-than-expected respiratory season that pressures revenue and product utilization.
Cost actions failing to offset lower revenue or adverse business mix.
Failure to deliver working-capital improvement after withdrawing free-cash-flow guidance.

WatchKey bullets

Third-quarter execution checkpoint

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $13 (p=50%)

Target spread vs base: +23% / -38%

Scenario probabilities

Bull Target: $16 (p=25%)Base Target: $13 (p=50%)Bear Target: $8 (p=25%)

Commentary

News tone is negative because the Q2 headline beat was followed by sharply reduced annual guidance and withdrawn free-cash-flow guidance. Stored coverage reported an immediate decline from $16.32 before earnings to $14.62, and the September 14 anchor of $11.12 indicates that weakness subsequently persisted. No reliable social, options-skew, short-interest, employee-sentiment, or post-print analyst-revision data were supplied; the zero values above denote unavailable inputs rather than neutral readings.

As of 2026-09-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

China, respiratory, and cash-flow pressure
Cash conversion and balance-sheet repair

Scenarios

Bull Target (Scenario probability)

$16 / p=25% prob

Base Target (Scenario probability)

$13 / p=50% prob

Bear Target (Scenario probability)

$8 / p=25% prob

Analysis 2026-09-15 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.45

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-05
Third-quarter execution checkpoint
The next reporting cycle should test whether ex-China growth, Point of Care momentum, and cost mitigation can offset the pressures behind August's guidance reduction. Q2 revenue grew 3%, Point of Care grew 16%, and adjusted EBITDA margin improved 310 basis points to 20.5% [#SEC-8K-2026-08-06].
Prob 65.00% • Move 10.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

China, respiratory, and cash-flow pressure
2026-12-31
Management cited China IVD-pricing uncertainty and softer global respiratory demand, reduced 2026 revenue, adjusted EBITDA, and adjusted EPS guidance, and withdrew free-cash-flow guidance. Persistent weakness could force another reset [#SEC-8K-2026-08-06].
Prob 70% • Move -15% • Priced-in 70%

Long-term Catalysts

Months to a year

Cash conversion and balance-sheet repair
2027-12-31
Long-term upside depends on converting core-franchise resilience into sustainable cash generation, working-capital improvement, and deleveraging. Management called cash conversion its top priority, but withdrawal of free-cash-flow guidance leaves progress unproven [#SEC-8K-2026-08-06].
Prob 45% • Move 30% • Priced-in 25%

Risks

A weaker-than-expected respiratory season that pressures revenue and product utilization.
Cost actions failing to offset lower revenue or adverse business mix.
Failure to deliver working-capital improvement after withdrawing free-cash-flow guidance.
Further deterioration in China following changes or uncertainty around IVD pricing.
Leverage and balance-sheet constraints limiting strategic flexibility.
Low analyst coverage and unavailable target-count data make consensus valuation signals fragile.

Peers

Symbol	Summary
ABT	A diagnostics participant but much larger and more diversified; useful mainly as a quality benchmark rather than a close valuation peer. QDEL carries materially greater execution and balance-sheet sensitivity.
BSX	A broad medtech company rather than a direct diagnostics peer. Its stronger structural growth profile highlights QDEL's need to demonstrate durable product execution, margin stability, and cash conversion.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-15

Loading AI feed…

Symbol

Summary

ABT

A diagnostics participant but much larger and more diversified; useful mainly as a quality benchmark rather than a close valuation peer. QDEL carries materially greater execution and balance-sheet sensitivity.

BSX

A broad medtech company rather than a direct diagnostics peer. Its stronger structural growth profile highlights QDEL's need to demonstrate durable product execution, margin stability, and cash conversion.